Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 25595-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- TM9SF4 antibody
- Antibody type
- Polyclonal
- Description
- TM9SF4 antibody (Cat. #25595-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references TM9SF4 Is a Crucial Regulator of Inflammation and ER Stress in Inflammatory Bowel Disease.
TM9SF4 is an F-actin disassembly factor that promotes tumor progression and metastasis.
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells.
TM9SF4 is a novel regulator in lineage commitment of bone marrow mesenchymal stem cells to either osteoblasts or adipocytes.
Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells.
Xie M, Mak JWY, Yu H, Cheng CTY, Chan HCH, Chan TT, Lau LHS, Wong MTL, Ko WH, Jiang L, Yao X
Cellular and molecular gastroenterology and hepatology 2022;14(2):245-270
Cellular and molecular gastroenterology and hepatology 2022;14(2):245-270
TM9SF4 is an F-actin disassembly factor that promotes tumor progression and metastasis.
Meng Z, Li Z, Xie M, Yu H, Jiang L, Yao X
Nature communications 2022 Sep 29;13(1):5728
Nature communications 2022 Sep 29;13(1):5728
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells.
Yu Y, Song Y, Cheng L, Chen L, Liu B, Lu D, Li X, Li Y, Lv F, Xing Y
Journal of experimental & clinical cancer research : CR 2022 Jun 2;41(1):188
Journal of experimental & clinical cancer research : CR 2022 Jun 2;41(1):188
TM9SF4 is a novel regulator in lineage commitment of bone marrow mesenchymal stem cells to either osteoblasts or adipocytes.
Yu L, Xie M, Zhang F, Wan C, Yao X
Stem cell research & therapy 2021 Nov 13;12(1):573
Stem cell research & therapy 2021 Nov 13;12(1):573
Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells.
Zhu Y, Xie M, Meng Z, Leung LK, Chan FL, Hu X, Chi K, Liu C, Yao X
Oncogene 2019 Jul;38(29):5778-5791
Oncogene 2019 Jul;38(29):5778-5791
No comments: Submit comment
No validations: Submit validation data